Compare YDDL & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDDL | STTK |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | Philippines | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.4M | 275.9M |
| IPO Year | 2025 | 2020 |
| Metric | YDDL | STTK |
|---|---|---|
| Price | $6.75 | $3.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.20 |
| AVG Volume (30 Days) | 69.7K | ★ 908.8K |
| Earning Date | 02-23-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 310.92 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $62,922,700.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $44.41 | ★ N/A |
| Revenue Growth | ★ 118.15 | N/A |
| 52 Week Low | $3.61 | $0.69 |
| 52 Week High | $8.89 | $4.89 |
| Indicator | YDDL | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 60.41 | 50.57 |
| Support Level | $6.01 | $3.92 |
| Resistance Level | $7.38 | $4.46 |
| Average True Range (ATR) | 0.50 | 0.37 |
| MACD | 0.08 | -0.12 |
| Stochastic Oscillator | 62.50 | 7.81 |
One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of Philippines. The company process raw materials and generate final products that include copper alloy ingot, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap and industrial recycling. By providing lower-cost alternatives for processing recycled materials, It is not only Contributing to environmental sustainability but also highlight its role as a modern and specialized recycling company.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.